Zymeworks Inc. (ZYME)
| Market Cap | 2.06B |
| Revenue (ttm) | 105.97M |
| Net Income (ttm) | -81.13M |
| Shares Out | 73.75M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | 22.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 421,291 |
| Open | 28.61 |
| Previous Close | 28.56 |
| Day's Range | 27.92 - 28.89 |
| 52-Week Range | 10.86 - 29.75 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 38.90 (+39.25%) |
| Earnings Date | May 7, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $38.9, which is an increase of 39.25% from the latest price.
News
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Biotech innovation is gaining renewed investor recognition, driving sector growth and M&A activity. A strong financial position enables sustained R&D, strategic acquisitions, and shareholder returns, with a robust pipeline and key catalysts ahead, including FDA reviews and pivotal clinical data.
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable to...
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is evolving into a diversified asset aggregator, combining robust internal R&D with strategic royalty and asset acquisitions. Strong financials, highlighted by a $250 million Royalty Pharma deal and a $125 million share repurchase program, support a long runway and ongoing pipeline expansion in oncology and immunology.
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pi...
Zymeworks Transcript: The Citizens Life Sciences Conference 2026
The company is leveraging a royalty-driven model, with a strong cash position and multiple assets advancing through clinical development. Key milestones include regulatory filings for zanidatamab, pivotal studies for pasritamig, and new data from its ADC pipeline, with strategic deals expected this year.
Zymeworks Transcript: Leerink Global Healthcare Conference 2026
The organization is prioritizing R&D and partnerships, deploying capital from royalties and milestones into pipeline development, asset aggregation, and share buybacks. Zanidatamab's strong clinical results are expected to transform care in gastric and breast cancers, while new ADCs and T-cell engagers advance in the pipeline.
Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference
The company is leveraging a hybrid biotech and royalty model, supported by strong clinical data for zanidatamab and a robust pipeline of ADCs and T-cell engagers. Recent $250M financing and milestone payments provide a strong cash runway, enabling flexible capital deployment and ongoing business development.
Zymeworks Earnings Call Transcript: Q4 2025
Strong phase 3 results for Zanidatamab in HER2-positive GEA support global regulatory filings and multi-billion dollar peak sales potential. Strategic $250M royalty-backed financing and disciplined capital allocation extend cash runway beyond 2028, with robust R&D and share repurchases ongoing.
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in fundin...
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip...
Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference
A transformative year saw zanidatamab poised as a new standard in HER2-overexpressing GEA, driving a strategic shift toward a hybrid model blending R&D innovation with long-term royalty streams. The pipeline is expanding, partnerships are central, and financial strength supports future growth.
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip...
Zymeworks Outlines Strategic Priorities and Outlook for 2026
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip...
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip...
Zymeworks Announces Participation in Upcoming Conferences
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial...
Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference
A hybrid royalty and R&D strategy is driving long-term value, leveraging internal and external assets for diversified cash flows. Early clinical data from the ADC portfolio, especially ZW191, supports potential partnerships and broad patient coverage.
Zymeworks Transcript: Investor Update
A new strategy was announced, shifting to a hybrid model focused on royalty aggregation, selective R&D, and strategic partnerships, leveraging strong financials and positive clinical data. Capital will be allocated between royalty acquisitions, R&D, and share buybacks, aiming for sustainable, compounding growth and attractive shareholder returns.